Table 1.
Comparison of histological submissions, which contain one biopsy (= 1 biopsy), based on the age groups pre-, peri- and post-screening
| Total | Age group | p-value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-screening (< 50 years) | Peri-screening (50–69 years) | Post-screening (≥ 70 years) | ||||||||
|
n (%) |
n (%) |
n (%) |
n (%) |
|||||||
| Localization | Total number [n] | 6.329 | 0.007 a | |||||||
| C50.1 | 109 (1,7) | 34 (1.4) | 39 (1.5) | 36 (2.7) | ||||||
| C50.2 | 383 (6.1) | 149 (6.2) | 162 (6.2) | 72 (5.4) | ||||||
| C50.3 | 205 (3.2) | 80 (3.3) | 76 (2.9) | 49 (3.7) | ||||||
| C50.4 | 1.377 (21.8) | 530 (22.1) | 586 (22.5) | 261 (19.7) | ||||||
| C50.5 | 305 (4.8) | 128 (5.3) | 120 (4.6) | 57 (4.3) | ||||||
| C50.6 | 36 (0.6) | 5 (0.2) | 22 (0.8) | 9 (0.7) | ||||||
| C50.8 | 1.197 (18.9) | 463 (19.3) | 493 (18.9) | 241 (18.2) | ||||||
| C50.9 | 2.717 (42.9) | 1.008 (42.1) | 1.110 (42.6) | 599 (45.2) | ||||||
| B-classification | Total number [n] | 4.433 | 0.000a | |||||||
| B1 | 151 (3.4) | 78 (4.5) | 55 (3.3) | 18 (1.7) | ||||||
| B2 | 1.408 (31.8) | 879 (50.5) | 406 (24.7) | 123 (11.7) | ||||||
| B3 | 283 (6.4) | 151 (8.7) | 93 (5.6) | 39 (3.7) | ||||||
| B4 | 53 (1.2) | 12 (0.7) | 24 (1.5) | 17 (1.6) | ||||||
| B5a | 260 (5.9) | 73 (4.2) | 123 (7.5) | 64 (6.1) | ||||||
| B5b | 2.232 (50.3) | 536 (30.8) | 930 (56.5) | 766 (73.2) | ||||||
| B5c | 46 (1.0) | 10 (0.6) | 16 (1.0) | 20 (1.9) | ||||||
| B5d | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| Carcinoma | Total number [n] | 3.084 | ||||||||
| Invasive ductal carcinoma/ invasive carcinoma NST | 2.318 (75.2) | 573 (81.3) | 1.062 (75.4) | 683 (70.3) | 0.000b | |||||
| Invasive lobular carcinoma | 486 (15.8) | 82 (11.6) | 234 (16.6) | 170 (17.5) | 0.000 b | |||||
| Invasive carcinoma with medullary features/ medullary carcinoma/atypical medullary carcinoma | 59 (1.9) | 24 (3.4) | 22 (1.6) | 13 (1.3) | 0.175 b | |||||
| Other invasive carcinomas | 221 (7.1) | 26 (3.7) | 90 (6.4) | 105 (10.9) | ||||||
| Tubular carcinoma | 50 (1.6) | 8 (1.1) | 27 (1.9) | 15 (1.5) | 0.004b | |||||
| Invasive papillary carcinoma/solid papillary carcinoma | 36 (1.2) | 4 (0.6) | 12 (0.9) | 20 (2.1) | 0.005b | |||||
| Metaplastic carcinoma | 6 (0.2) | 0 (0.0) | 2 (0.1) | 4 (0.4) | 0.135b | |||||
| Mucinous carcinoma | 65 (2.1) | 7 (1.0) | 17 (1.2) | 41 (4.2) | 0.000b | |||||
| Other subtypes | 36 (1.2) | 5 (0.7) | 16 (1.1) | 15 (1.5) | 0.046b | |||||
| Metastases | 18 (0.6) | 1 (0.1) | 12 (0.9) | 5 (0.5) | 0.006b | |||||
| Other malignant tumors | 9 (0.3) | 1 (0.1) | 4 (0.3) | 4 (0.4) | 0.368b | |||||
| Multiple malignant carcinomas | 1 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0.386b | |||||
| In-situ lesions | Total number [n] | 529 | ||||||||
| Atypical epithelial proliferation of ductal type/ DCIS non high grade /ADH | 300 (56.7) | 85 (55.2) | 150 (56.6) | 65 (59.1) | 0.000b | |||||
| Ductales carcinoma in situ high grade | 171 (32.3) | 49 (31.8) | 83 (31.3) | 39 (35.5) | 0.000b | |||||
| Lobular intraepithelial neoplasia | 16 (3.0) | 4 (2.6) | 11 (4.2) | 1 (0.9) | 0.007b | |||||
| Flat epithelial Atypia | 23 (4.3) | 13 (8.4) | 9 (3.4) | 1 (0.9) | 0.008b | |||||
| Multiple in-situ carcinoma | 19 (3.6) | 3 (1.9) | 12 (4.5) | 4 (3.6) | 0.021b | |||||
| Elston & Ellis grading system | Total number [n] | 1.602 | 0.025a | |||||||
| G1 | 463 (28.9) | 96 (25.3) | 186 (28.9) | 181 (31.3) | ||||||
| G2 | 899 (56.1) | 212 (55.8) | 358 (55.6) | 329 (56.9) | ||||||
| G3 | 240 (15.0) | 72 (18.9) | 100 (15.5) | 68 (11.8) | ||||||
| Estrogen receptor status | Total number [n] | 3.503 | 0.000a | |||||||
| Negative | 506 (14.4) | 150 (18.3) | 229 (14.1) | 127 (11.9) | ||||||
| Positive (weak expression) | 145 (4.1) | 45 (5.5) | 64 (4.0) | 36 (3.4) | ||||||
| Positive (moderate expression) | 661 (18.9) | 228 (27.9) | 286 (17.7) | 147 (13.8) | ||||||
| Positive (strong expression) | 2.191 (62.5) | 395 (48.3) | 1.040 (64.2) | 756 (70.9) | ||||||
| Progesterone receptor status | Total number [n] | 3.497 | 0.099a | |||||||
| Negative | 950 (27.2) | 226 (27.7) | 448 (27.7) | 276 (25.9) | ||||||
| Positive (weak expression) | 237 (6.8) | 43 (5.3) | 123 (7.6) | 71 (6.7) | ||||||
| Positive (moderate expression) | 838 (24.0) | 178 (21.8) | 395 (24.4) | 265 (24.9) | ||||||
| Positive (strong expression) | 1.472 (42.1) | 369 (45.2) | 651 (40.3) | 452 (42.5) | ||||||
| HER2 status | Total number [n] | 3.068 | 0.000a | |||||||
| Negative | 2.656 (86.6) | 585 (83.1) | 1.189 (84.9) | 882 (91.6) | ||||||
| Positive | 412 (13.4) | 119 (16.9) | 212 (15.1) | 81 (8.4) | ||||||
| Positive (% within HER2-Status) | 119 (28.9) | 212 (51.5) |
81 (19.7) |
|||||||
| Ki-67-index (grouped) | Total number [n] | 927 | 0.160a | |||||||
| ≤ 10 | 110 (11.9) | 22 (10.0) | 41 (11.3) | 47 (13.7) | ||||||
| 10–20 | 219 (23.6) | 43 (19.5) | 83 (22.9) | 93 (27.1) | ||||||
| 20–25 | 105 (11.3) | 25 (11.3) | 42 (11.6) | 38 (11.1) | ||||||
| 25–50 | 299 (32.3) | 75 (33.9) | 119 (32.8) | 105 (30.6) | ||||||
| > 50 | 153 (16.5) | 48 (21.7) | 63 (17.4) | 42 (12.2) | ||||||
| Unclassifiable | 41 (4.4) | 8 (3.6) | 15 (4.1) | 18 (5.2) | ||||||
| IHC based molecular subtypes | Total number [n] | 1.322 | 0.000a | |||||||
| Triple-negative (ER- PR- HER2-) | 301 (22.8) | 99 (28.2) | 123 (22.1) | 79 (19.1) | ||||||
| Luminal A | 297 (22.5) | 60 (17.1) | 108 (19.4) | 129 (31.2) | ||||||
| Luminal B | 622 (47.0) | 160 (45.6) | 277 (49.7) | 185 | (44.7) | |||||
| HER2 positive | 102 (7.7) | 32 (9.1) | 49 (8.8) | 21 (5.1) | ||||||
aFishers exact test
bChi square tes